A European study combined epidemiology and radiobiology to assess cancer risks in the breast, lung, thyroid and digestive tract after exposures to ionizing radiation with low doses
Due to lack of statistical power and competing risk factors not under control, conventional epidemiology has limitations in studying cancer risks after exposure to ionizing radiation with low dose. The EU-funded EPIRADBIO (Combining epidemiology and radiobiology to assess cancer risks in the breast, lung, thyroid and digestive tract after exposures to ionizing radiation with total doses in the order of 100 mSv or below) project integrated molecular biology in the modelling of radiation-induced disease processes and improved cancer risk estimates based on epidemiological data.
Further details: Molecular markers of radiation-induced cancer improve risk estimates